Zoficonazole was developed as an antibacterial and an antifungal agent. Information about the current use of this compound is not available.

Traxanox is a diuretic agent possessing an uricosuric effect in animals. The diuretic and uricosuric effects of the drug have also been demonstrated in normotensive healthy subjects. The chronic administration of traxanox reduces serum uric acid level as well as blood pressure in patients with mild to moderate hypertension. This reduction in serum uric acid is due in part to a traxanox-induced elevation of urinary uric acid excretion. Traxanox sodium stimulates the phagocytic activity of leukocytes or macrophages and prevents the drug-induced suppression of the phagocytic activity of these cells. Traxanox may be clinically effective in treating patients with nasal allergies. The mode of action of traxanox on inflammatory responses resembles that of D-penicillamine or levamisole, so that it may prove to be clinically effective in treating rheumatoid arthritis. Also, traxanox may be effective for the treatment of allergic bronchial asthma.

Tienopramine is a benzazepine derivative patented by Roussel-UCLAF as antidepressive agent. Tienopramine is a tricyclic antidepressant and an imipramine analogue where one of the benzene rings has been replaced with a thiophene ring.

PPI-2458 is a synthetic derivative of fumagillin with antineoplastic and cytotoxic properties. PPI-2458 irreversibly inhibits the enzyme methionine aminopeptidase type 2 (MetAP2), thereby preventing abnormal cell growth and angiogenesis. PPI-2458 is reported to have a better toxicity profile compared to other agents of its class. In a phase 1 clinical study, PPI-2458 was administered to patients with non-Hodgkin lymphoma. The data confirm the participation of active metabolites in the in vivo efficacy of PPI-2458. In in vitro studies, osteoclast formation and activity were inhibited by PPI-2458, a mechanism not previously attributed to MetAP-2 inhibition. PPI-2458 treatment reduced synovial and osteochondral angiogenesis, synovial inflammation, joint damage, and pain behavior. PPI-2458 exerts disease-modifying activity in experimental arthritis through its direct inhibition of several pathophysiologic processes of this disease. These results provide a rationale for assessing the potential of PPI-2458 as a novel rheumatoid arthritis therapy.

Belfosdil (or SR-7037) is an antihypertensive calcium channel blocker.

Nalmexone is an opioid partial agonist or mixed agonist-antagonist with both analgesic and narcotic antagonist properties. In preclinical models parenteral nalmexone was a moderately active antagonist and therefore might have low abuse potential. At the same time, early work in man indicated analgesic activity in doses above 20 mg.

Posizolid (AZD2563 or AZD5847) is an oxazolidinone, identified from an antibiotic research programme which aimed to synthesise agents that inhibited all Gram-positive bacteria, including multiresistant strains likely to be encountered clinically. Oxazolidinones bind to the 50S ribosomal subunit and inhibit the initiation phase of translation. Posizolid had been in phase II clinical trials for the treatment of tuberculosis. However, this study was discontinued.

Prazitone (also known as AGN-511) is a barbiturate derivative patented by Aspro-Nicholas Ltd. as a non-sedating anxiolytic and antidepressant

Valofane is an atypical barbiturate. It is a tautomer (and prodrug) of proxibarbal Valofane is a neurotropic drug. It has sedative and hypnotic action.

Trithiozine is an alkoxythiobenzamide said to have antisecretory and tranquillising properties without anticholinergic, antihistaminic, or ganglion-blocking effects. Trithiozine in animal studies proved to have a marked anti-secretory and anti-ulcer effect, along with a very low acute and chronic toxicity. Clinical trials with trithiozine have been performed in some European countries. The results of these trials, most of which were conducted on a double-blind basis, and including already several hundreds of patients, have shown that oral trithiozine: exerts a very significant action on both basal and stimulated gastric acid secretion, without a rebound hypersecretion; promotes, in most patients, a complete endoscopic healing of peptic ulcer, in addition to an early symptomatic relief; has a mild sedative action; does not affect the pancreatic secretion; is well tolerated even for long-term (up to 10 months) treatments.